This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Studies Using Debrisoquin

James W. Maas, MD; Salvador A. Contreras, MD; Ermias Seleshi, MD; Charles L. Bowden, MD

Arch Gen Psychiatry. 1988;45(6):553-559.

Abstract
• Debrisoquin sulfate, a monoamine oxidase inhibitor that does not enter the brain, was administered to 23 schizophrenic subjects. Plasma, cerebrospinal fluid (CSF), and urine samples were obtained before and during debrisoquin administration and were assayed for their content of norepinephrine and dopamine metabolites, ie, 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and dihydroxyphenylacetic acid. The severity of the patient's schizophrenic symptoms was also assessed with several types of rating scales. During debrisoquin administration there were significant reductions in plasma, urine, and CSF MHPG levels. Regression analyses suggested that the reduction in CSF MHPG level was probably due to the reduction in plasma MHPG level, which contributes to the CSF MHPG pool. Debrisoquin administration was not associated with changes in CSF HVA level, although it did produce marked reductions in plasma and urinary HVA and dihydroxyphenylacetic acid levels. Significant correlations between plasma and CSF concentrations of HVA were noted during, but not before, debrisoquin administration. Before debrisoquin administration there were trends toward positive relationships between symptom severity and plasma HVA concentrations, which became stronger and statistically significant during debrisoquin administration. These data suggest that debrisoquin may be used as a research tool to create a condition in which measures of HVA in peripheral body fluids reflect dopamine system function and metabolism within the central nervous system.

Author Affiliations
From the Department of Psychiatry, The University of Texas Health Science Center at San Antonio (Drs Maas, Seleshi, and Bowden), and Audie L. Murphy Memorial Veterans' Hospital, San Antonio (Dr Contreras).

Footnotes
Accepted for publication Nov 17, 1987.

Reprint requests to Department of Psychiatry, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-7792 (Dr Maas).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects
Giltay et al.
J Endocrinol 2005;187:109-116.
ABSTRACT | FULL TEXT  

Effects of Neuroleptic Treatment on Symptoms of Schizophrenia and Plasma Homovanillic Acid Concentrations
Davidson et al.
Arch Gen Psychiatry 1991;48:910-913.
ABSTRACT  

Changes in Plasma Homovanillic Acid Concentrations in Schizophrenic Patients Following Neuroleptic Discontinuation
Davidson et al.
Arch Gen Psychiatry 1991;48:73-76.
ABSTRACT  

Cerebrospinal Fluid and Plasma Monoamine Metabolites and Their Relation to Psychosis: Implications for Regional Brain Dysfunction in Schizophrenia
Pickar et al.
Arch Gen Psychiatry 1990;47:641-648.
ABSTRACT  

Circadian Variation of Plasma Homovanillic Acid Levels Is Attentuated by Fluphenazine in Patients With Schizophrenia
Doran et al.
Arch Gen Psychiatry 1990;47:558-563.
ABSTRACT  

Effects of Renal Clearance on Plasma Concentrations of Homovanillic Acid: Methodologic Cautions
Potter et al.
Arch Gen Psychiatry 1989;46:558-562.
ABSTRACT  

Plasma Monoamine Metabolites in Psychotic Disorders
Bowers
Arch Gen Psychiatry 1988;45:595-596.
ABSTRACT